

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

ETAS ID: TM513088

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
CRG SERVICING LLP LLC		03/06/2019	Limited Liability Company:
RECEIVING PARTY DATA			
Name:	SYNERGY PHARMACEUTICALS INC.		
Street Address:	TWO EXECUTIVE DRIVE		
Internal Address:	SUITE 450		
City:	SOMERSET		
State/Country:	NEW JERSEY		
Postal Code:	08873		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Serial Number:	87167674	KOMFIENCE	
Serial Number:	87532128	POOP TROOP	
Registration Number:	5073973	SYNERGY PHARMACEUTICALS	
Registration Number:	5242709	TRULANCE	
Serial Number:	87392678	TRULANCE	
CORRESPONDENCE DATA			
Fax Number:	2122182200		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	212-218-2100		
Email:	mmiglio@venable.com		
Correspondent Name:	VENABLE LLP		
Address Line 1:	1290 AVENUE OF THE AMERICAS		
Address Line 2:	19TH FLOOR		
Address Line 4:	NEW YORK, NEW YORK 10104-3800		
NAME OF SUBMITTER:	ALICIA A. RUSSO		
SIGNATURE:	/Alicia A. Russo/		
DATE SIGNED:	03/06/2019		

CH \$140.00 87167674

Total Attachments: 12

source=46053317_3-signed#page1.tif
source=46053317_3-signed#page2.tif
source=46053317_3-signed#page3.tif
source=46053317_3-signed#page4.tif
source=46053317_3-signed#page5.tif
source=46053317_3-signed#page6.tif
source=46053317_3-signed#page7.tif
source=46053317_3-signed#page8.tif
source=46053317_3-signed#page9.tif
source=46053317_3-signed#page10.tif
source=46053317_3-signed#page11.tif
source=46053317_3-signed#page12.tif

**RELEASE AND TERMINATION OF PATENT AND TRADEMARK
SECURITY INTERESTS**

This RELEASE AND TERMINATION OF PATENT AND TRADEMARK SECURITY INTERESTS (“*Release*”) is made and effective as of March 6, 2019, and granted by CRG SERVICING LLC (the “*Administrative Agent*”), as administrative agent and collateral agent for the Secured Parties (as such term is defined in the IP Security Agreement referred to below), in favor of SYNERGY PHARMACEUTICALS INC. (the “*Grantor*”) and its successors and assigns.

WHEREAS, the Grantor is party to that certain Security Agreement, dated as of September 1, 2017 (the “*Security Agreement*”), among the Grantor, Synergy Advanced Pharmaceuticals, Inc., and the Administrative Agent (capitalized terms used herein without definition shall have the meanings set forth in the Security Agreement);

WHEREAS, pursuant to the Security Agreement, the Grantor executed and delivered to the Administrative Agent that certain Patent and Trademark Security Agreement dated as of September 1, 2017 (the “*IP Security Agreement*”);

WHEREAS, the IP Security Agreement was amended and supplemented by that certain Amendment dated as of December 8, 2018 (the “*IP Security Amendment*”, and together with the IP Security Agreement, the “*IP Security Documents*”);

WHEREAS, pursuant to the Security Agreement, the IP Security Agreement and the IP Security Amendment, as collateral security for the payment in full when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, Grantor pledged and granted to the Secured Parties a security interest in all of Grantor’s right, title and interest in, to and under the Patent Collateral and Trademark Collateral (as such terms are defined below in Section 2 and Section 3, respectively), as collateral security for the prompt and complete payment and performance when due of all the Secured Obligations (as defined in the Security Agreement);

WHEREAS, the IP Security Agreement was recorded with the United States Patent and Trademark Office on September 5, 2017: (i) at **Reel 043488, Frame 0741** with respect to the patents and patent applications set forth on **Schedule A** attached thereto; and (ii) at **Reel 6147, Frame 0430** with respect to the trademarks and trademark applications set forth on **Schedule B** attached thereto;

WHEREAS, the IP Security Amendment was recorded with the United States Patent and Trademark Office on December 10, 2018, at **Reel 047729, Frame 0951** with respect to the patents and patent applications set forth on **Schedule A** attached thereto; and

WHEREAS, the Grantor has requested that the Administrative Agent enter into this Release in order to effectuate, evidence and record the release and reassignment to the Grantor of any and all right, title and interest the Administrative Agent and the other Secured Parties may have in the Patent Collateral and the Trademark Collateral.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent hereby confirms and agrees as follows:

1. Termination of IP Security Documents. The Administrative Agent, on behalf of itself and the Secured Parties, their successors and assigns, hereby terminates the IP Security Documents.

2. Release of Security Interests in Patent Collateral. The Administrative Agent, on behalf of itself and the Secured Parties, their successors, legal representatives and assigns, hereby terminates, releases and discharges any and all security interests that it has pursuant to the Security Agreement and the IP Security Documents in any and all right, title and interest of the Grantor, and reassigns to the Grantor any and all right, title and interest that it may have, in, to and under the following (collectively, the “*Patent Collateral*”): all patents and patent applications, in each case whether then owned by Grantor or thereafter acquired and whether then existing or thereafter coming into existence, including without limitation those listed on Schedule I hereto, and all related patents and applications thereto, including all reissuances, continuations, continuations-in-part, revisions, extensions, re-examinations thereof, any patents and patent applications claiming priority to said patents and patent applications or from which said patents and patent applications claim priority, and pending applications associated therewith.

3. Release of Security Interests in Trademark Collateral. The Administrative Agent, on behalf of itself and the Secured Parties, their successors, legal representatives and assigns, hereby terminates, releases and discharges any and all security interests that it has pursuant to the Security Agreement and the IP Security Documents in any and all right, title and interest of the Grantor, and reassigns to the Grantor any and all right, title and interest that it may have, in, to and under the following (collectively, the “*Trademark Collateral*”): all of the trademarks, whether then owned or at any time thereafter acquired, of Grantor that were registered with, or for which applications for registration had been filed with, the United States Patent and Trademark Office, including the trademarks listed on **Schedule II** hereto, and all registrations and pending applications associated therewith (excluding any application for registration of a trademark filed on an intent-to-use basis solely to the extent that the grant of a security interest in any such trademark application would materially adversely affect the validity or enforceability of the resulting trademark registration or result in cancellation of such trademark application).

4. Recordation. The Administrative Agent hereby authorizes Grantor, or Grantor’s authorized representative, to record this Release with the United States Patent and Trademark Office.


5. Further Assurances. The Administrative Agent agrees to take all further actions, and provide to the Grantor and its successors and assigns all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or other instruments, as the Grantor and their successors and assigns may reasonably request in order to confirm, effectuate or record this Release.

6. Governing Law. This Release shall be governed by, and construed in accordance with, the law of the State of New York (and, as applicable, the Bankruptcy Code), without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply.

IN WITNESS WHEREOF, the Administrative Agent has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

CRG SERVICING LLC

as Administrative Agent

By: 

Name: Andrei Dorenbaum

Title: Authorized Signatory

SCHEDULE I

PATENTS AND PATENT APPLICATIONS

A. IP Security Agreement: Reel 043488, Frame 0741

Owner	Title/Mark	Application No.	Application Date	Registration No.	Registration Date
Synergy Pharmaceuticals Inc.	GUANYLATE CYCLASE RECEPTOR AGONISTS FOR THE TREATMENT OF TISSUE INFLAMMATION AND CARCINOGENESIS	10/107,814	3/28/2002	7,041,786	5/9/2006
Synergy Pharmaceuticals Inc.	GUANYLATE CYCLASE RECEPTOR AGONISTS FOR THE TREATMENT OF TISSUE INFLAMMATION AND CARCINOGENESIS	11/347,115	2/2/2006	7,799,897	9/21/2010
Synergy Pharmaceuticals Inc.	GUANYLATE CYCLASE RECEPTOR AGONISTS FOR THE TREATMENT OF TISSUE INFLAMMATION AND CARCINOGENESIS	12/763,707	4/20/2010	8,114,831	2/14/2012
Synergy Pharmaceuticals Inc.	GUANYLATE CYCLASE RECEPTOR AGONISTS FOR THE TREATMENT OF TISSUE INFLAMMATION AND CARCINOGENESIS	13/339,785	12/29/2011	8,637,451	1/28/2014
Synergy Pharmaceuticals Inc.	GUANYLATE CYCLASE RECEPTOR AGONISTS FOR THE TREATMENT OF TISSUE INFLAMMATION AND CARCINOGENESIS	14/137,256	12/20/2013		
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	12/133,344	6/4/2008	7,879,802	2/1/2011
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF	12/630,654	12/3/2009	8,969,514	3/3/2015

Owner	Title/Mark	Application No.	Application Date	Registration No.	Registration Date
	HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES				
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	13/010,267	1/20/2011	8,716,224	5/6/2014
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	13/857,283	4/5/2013	8,901,075	12/2/2014
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	14/528,257	10/30/2014	9,266,926	2/23/2016
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, CORONARY HEART DISEASE, GALLSTONE, OBESITY AND OTHER CARDIOVASCULAR DISEASES	14/742,456	6/17/2015		
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL	15/049,740	2/22/2016		

Owner	Title/Mark	Application No.	Application Date	Registration No.	Registration Date
	DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS				
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	15/471,462	3/28/2017		
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	14/228,843	3/28/2014	9,238,677	1/19/2016
Synergy Pharmaceuticals Inc.	METHOD OF INHIBITING BILE ACID ABSORPTION BY ADMINISTERING AN AGONIST OF A GUANYLATE CYCLASE RECEPTOR	13/513,224	12/3/2010	9,089,612	7/28/2015
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	12/478,505	6/4/2009	8,207,295	6/26/2012
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	13/467,703	5/9/2012	8,357,775	1/22/2013
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL	13/716,874	12/17/2012	8,497,348	7/30/2013

Owner	Title/Mark	Application No.	Application Date	Registration No.	Registration Date
	DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS				
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	14/831,293	8/20/2015		
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	12/504,288	7/16/2009	8,034,782	10/11/2011
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	14/632,314	2/26/2015	9,505,805	11/29/2016
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	15/297,688	10/19/2016		Abandoned
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	13/226,300	9/6/2011	8,367,800	2/5/2013
Synergy Pharmaceuticals	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE	13/731,483	12/31/2012	8,569,246	10/29/2013

Owner	Title/Mark	Application No.	Application Date	Registration No.	Registration Date
Inc.	TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS				
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	13/955,710	7/31/2013	8,664,354	3/4/2014
Synergy Pharmaceuticals Inc.	FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE	14/301,812	6/11/2014		
Synergy Pharmaceuticals Inc.	PROCESS OF PREPARING GUANYLATE CYCLASE C AGONIST	15/405,787	1/13/2017		
Synergy Pharmaceuticals Inc.	PROCESS OF PREPARING GUANYLATE CYCLASE C AGONIST	14/001,638	3/1/2012	9,580,471	2/28/2017
Synergy Pharmaceuticals Inc.	FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE	14/845,644	9/4/2015	9,610,321	4/4/2017
Synergy Pharmaceuticals Inc.	FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE	15/467,631	3/23/2017		
Synergy Pharmaceuticals Inc.	FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE	15/467,648	3/23/2017		
Synergy Pharmaceuticals Inc.	FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE	13/421,769	3/15/2012	9,616,097	4/11/2017
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF	15/026,560	10/9/2014		

Owner	Title/Mark	Application No.	Application Date	Registration No.	Registration Date
	PRO-INFLAMMATORY CYTOKINES				
Synergy Pharmaceuticals Inc.	COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS	14/207,749	3/13/2014	9,486,494	11/8/2016
Synergy Pharmaceuticals Inc.	COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS	15/272,873	9/22/2016		
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE AND THEIR USES	14/189,645	2/25/2014	9,545,446	1/17/2017
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE AND THEIR USES	15/381,680	12/16/2016		
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE AND THEIR USES	14/207,753	3/13/2014	9,708,367	7/18/2017
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE AND THEIR USES	15/622,526	6/14/2017		
Synergy Pharmaceuticals Inc.	FORMULATIONS AND METHODS FOR TREATING ULCERATIVE COLITIS	PCT/US2017/013017 16/069,313	1/11/2017		
Synergy Pharmaceuticals Inc.	COMPOSITIONS AND METHOD FOR THE TREATMENT AND DETECTION OF COLON CANCER	PCT/US2016/062902	11/18/2016		
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF OPIOID INDUCED DYSFUNCTIONS	15/026,563	10/10/2014		
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF OPIOID INDUCED DYSFUNCTIONS	14/944,499	11/18/2015		

Owner	Title/Mark	Application No.	Application Date	Registration No.	Registration Date
Synergy Pharmaceuticals Inc.	ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME	14/896,019	6/5/2014		
Synergy Pharmaceuticals Inc.	SUSTAINED AND IMMEDIATE RELEASE FORMULATIONS OF GUANYLATE				
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	15/184,574	6/16/2016		

B. IP Security Amendment: Reel 047729, Frame 0951

Owner	Title	Application No.	Application Date	Registration No.	Registration Date
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS	15/918,047	3/12/2018		
Synergy Pharmaceuticals Inc.	FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE	16/018,278	6/26/2018		
Synergy Pharmaceuticals Inc.	FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE	15/924,940	3/19/2018		
Synergy Pharmaceuticals Inc.	AGONISTS OF GUANYLATE CYCLASE AND THEIR USES	16/150,703	10/3/2018		
Synergy Pharmaceuticals Inc.	ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME	16/000,251	6/5/2018		

SCHEDULE II

TRADEMARKS AND TRADEMARK APPLICATIONS

A. IP Security Agreement: Reel 6147, Frame 0430

Owner	Trademark	Registration Number (if registered) Serial Number (if applied for only)	Registration Date (if Registered) or Filing Date (if applied for only)
Synergy Pharmaceuticals Inc.	KOMFIENCE	Serial Number: 87167674	9/12/2016
Synergy Pharmaceuticals Inc.	POOP TROOP	Serial Number: 87532128	7/18/2017
Synergy Pharmaceuticals Inc.	SYNERGY PHARMACEUTICALS	Registration Number: 5073973	11/1/2016
Synergy Pharmaceuticals Inc.	TRULANCE	Registration Number: 5242709	7/11/2017
Synergy Pharmaceuticals Inc.	TRULANCE and Design ***•*** Trulance	Serial Number: 87392678	3/30/2017

B. IP Security Amendment: None Listed / None Filed